Table 3.

Composition and observed responses from randomized runs in the D-optimal mixture design (n = 3).

Run	A: Omega-3 (%; X1)	B: Lauroglycol® 90 (%; X2)	C: Gelucire® 44/14 (%; X3)	Mean droplet size (nm; Y1)	DS15 (%; Y2)
1	27.89	57.11	15	277.2 ± 8.5	7 ± 0.12
2	27.67	42.41	29.92	195.4 ± 21	14.3 ± 0.11
3	27.41	30	42.59	269 ± 28.4	12.7 ± 0.59
4	40	37.88	22.13	212.6 ± 21.9	12.42 ± 0.007
5	40	37.88	22.13	204.9 ± 21.2	11.39 ± 0.77
6	27.41	30	42.59	295.2 ± 13.7	14.1 ± 0.62
7	15.37	46.56	38.07	386 ± 51	7.92 ± 0.07
8	37.26	30	32.74	210.5 ± 13.6	15.95 ± 0.20
9	27.89	57.11	15	282.4 ± 10.4	7.38 ± 0.02
10	18.55	65	16.45	296.2 ± 49.2	7.04 ± 0.09
11	19.78	54	26.22	210.6 ± 35.2	10.54 ± 0.11
12	15.37	46.56	38.07	251.9 ± 37.7	6.68 ± 1.14
13	10	39.92	50.08	322.8 ± 22.8	9.73 ± 4.41
14	10	65	25	284.3 ± 39	5.12 ± 0.16
15	15.37	46.56	38.07	274.1 ± 43.5	7.32 ± 0.73
16	10	30	60	362.7 ± 64.2	13.25 ± 1.72

Notes: Data represent the mean ± SD of three repeats (n = 3). Abbreviations used: DS₁₅, drug solubilization at 15 min; SD, standard deviation; X₁, oil; X₂, co-surfactant; X₃, surfactant; Y₁, mean droplet size; Y₂, drug solubilization at 15 min.